Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 positive |
Therapy | Pembrolizumab |
Indication/Tumor Type | salivary gland carcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | salivary gland carcinoma | predicted - sensitive | Pembrolizumab | Phase I | Actionable | In a Phase Ib trial (KEYNOTE-028), Keytruda (pembrolizumab) treatment resulted in an objective response rate of 12% (3/26) and a stable disease rate of 46% (12/26) in heavily pretreated patients with salivary gland carcinoma that had CD274 (PD-L1) expression in 1% or more of tumor or stroma cells by IHC, with a median duration of response of 4 months (PMID: 29462123; NCT02054806). | detail... 29462123 |
PubMed Id | Reference Title | Details |
---|---|---|
Preliminary results for the advanced salivary gland carcinoma cohort of the phase 1b KEYNOTE-028 study of pembrolizumab. | Full reference... | |
(29462123) | Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma: Findings of the Phase 1b KEYNOTE-028 Study. | Full reference... |